Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer

Linda J. W. Bosch, Geert Trooskens, Petur Snaebjornsson, Veerle M. H. Coupe, Sandra Mongera, Josien C. Haan, Susan D. Richman, Miriam Koopman, Jolien Tol, Tim de Meyer, Joost Louwagie, Luc Dehaspe, Nicole C. T. van Grieken, Bauke Ylstra, Henk M. W. Verheul, Manon van Engeland, Iris D. Nagtegaal, James G. Herman, Philip Quirke, Matthew T. SeymourCornelis J. A. Punt, Wim van Criekinge, Beatriz Carvalho, Gerrit A. Meijer*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)63140-63154
Number of pages15
JournalOncotarget
Volume8
Issue number38
DOIs
Publication statusPublished - 8 Sep 2017

Keywords

  • TNFRSF10C
  • biomarker
  • predictive
  • chemotherapy
  • CAIRO
  • RANDOMIZED CONTROLLED-TRIAL
  • COMBINATION CHEMOTHERAPY
  • PREDICTIVE BIOMARKERS
  • DNA METHYLATION
  • CELL-LINES
  • MRC FOCUS
  • APOPTOSIS
  • KRAS
  • PROGNOSIS
  • CETUXIMAB

Cite this

Bosch, L. J. W., Trooskens, G., Snaebjornsson, P., Coupe, V. M. H., Mongera, S., Haan, J. C., Richman, S. D., Koopman, M., Tol, J., de Meyer, T., Louwagie, J., Dehaspe, L., van Grieken, N. C. T., Ylstra, B., Verheul, H. M. W., van Engeland, M., Nagtegaal, I. D., Herman, J. G., Quirke, P., ... Meijer, G. A. (2017). Decoy receptor 1 (DCR1) promoter hypermethylation and response to irinotecan in metastatic colorectal cancer. Oncotarget, 8(38), 63140-63154. https://doi.org/10.18632/oncotarget.18702